The review proposal for this guidance is currently open for public consultation here.

Consultation on the review proposal will open on 28 October 2016 at 9.00am and close on 25 November 2016 at 9.00am.

In January 2016 NICE commenced the review of this guidance, to register as a stakeholder please contact us at medtech@nice.org.uk.

NICE has developed medical technology guidance on the SeQuent Please balloon catheter.

NICE medical technology guidance addresses specific technologies notified to NICE by manufacturers. The ‘case for adoption’ recommendations are based on the claimed advantages of introducing the specific technology compared with current management of the condition. This ‘case’ is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.

Hospital teams may want to use the SeQuent Please drug-coated balloon catheter as the evidence showed that it reduces restenosis of the coronary arteries more than drug-coated stent. It also reduces the need for further treatments and procedures to treat restenosis.

NICE has recommended that further research is carried out to compare the SeQuent Please drug-coated balloon catheter with other types of drug-eluting catheters and stents.

Next review: December 2015

Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

  • National Institute for Health and Care Excellence (NICE) accreditation logo